Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer
Active, not recruiting · NCT03820830 · Registry updated 2026-09-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer | Breast Cancer Recurrent | Active, not recruiting | Phase 3 | 2026-09-03 | NCT03820830 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| ETOP IBCSG Partners Foundation | 17 |
| Pfizer | 431 |
53 results · Page 1 of 3
Research sites
Swipe the table sideways for more columns.